推荐产品
等级
pharmaceutical primary standard
API类
amikacin
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
N([C@H]1[C@@H]([C@H]([C@@H]([C@H](C1)N)O[C@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CN)O)O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)N)O)CO)C(=O)[C@@H](O)CCN
InChI
1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
InChI key
LKCWBDHBTVXHDL-RMDFUYIESA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Amikacin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Amikacin Sulfate
- Amikacin Sulfate Injection
- Kanamycin Injection
- Kanamycin Sulfate
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险声明
危险分类
Skin Sens. 1
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
其他客户在看
A Bruce Montgomery et al.
Antimicrobial agents and chemotherapy, 58(7), 3714-3719 (2014-04-23)
The amikacin-fosfomycin inhalation system (AFIS) is a combination of 2 antibiotics and an in-line nebulizer delivery system that is being developed for adjunctive treatment of pneumonia caused by Gram-negative organisms in patients on mechanical ventilation. AFIS consists of a combination
Guilian Li et al.
PloS one, 10(2), e0119013-e0119013 (2015-02-20)
Isoniazid (INH) and rifampicin (RIF) are the two most effective drugs in tuberculosis therapy. Understanding the molecular mechanisms of resistance to these two drugs is essential to quickly diagnose multidrug-resistant (MDR) tuberculosis and extensive drug-resistant tuberculosis. Nine clinical Mycobacterium tuberculosis
Monika E Łysakowska et al.
Burns : journal of the International Society for Burn Injuries, 41(2), 364-371 (2014-08-26)
Acinetobacter baumannii isolates are responsible for a high number of wound infections. The reason of this study was to evaluate the activity of silver nanoparticles obtained by microexplosion against wide range of Acinetobacter spp. Susceptibility to silver nanoparticles was tested
Ming Zhang et al.
Antimicrobial agents and chemotherapy, 58(6), 3217-3223 (2014-03-26)
Oxazolidinones represent a new class of antituberculosis drugs that exert their function by inhibiting protein synthesis. Here, we compared the activities of three oxazolidinones, linezolid, PNU-100480, and AZD5847, against latent tuberculosis using a simple model employing the streptomycin-starved Mycobacterium tuberculosis
Sofiane Bakour et al.
Microbial drug resistance (Larchmont, N.Y.), 20(6), 604-609 (2014-06-06)
The aim of this study was to investigate the molecular support of resistance to carbapenems, aminoglycosides, and fluoroquinolones in Acinetobacter baumannii clinical isolates collected from Yemen hospital. Three A. baumannii were isolated in February 2013 from three patients hospitalized at
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门